Transmission of SARS-CoV-2: a review of viral, host, and environmental factors

EA Meyerowitz, A Richterman, RT Gandhi… - Annals of internal …, 2021 - acpjournals.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiologic agent of
coronavirus disease 2019 (COVID-19), has spread globally in a few short months …

The changing epidemiology of SARS-CoV-2

K Koelle, MA Martin, R Antia, B Lopman, NE Dean - Science, 2022 - science.org
We have come a long way since the start of the COVID-19 pandemic—from hoarding toilet
paper and wiping down groceries to sending our children back to school and vaccinating …

Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness

R Ke, PP Martinez, RL Smith, LL Gibson, A Mirza… - Nature …, 2022 - nature.com
The dynamics of SARS-CoV-2 replication and shedding in humans remain poorly
understood. We captured the dynamics of infectious virus and viral RNA shedding during …

Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity

R Subramanian, Q He… - Proceedings of the …, 2021 - National Acad Sciences
The contributions of asymptomatic infections to herd immunity and community transmission
are key to the resurgence and control of COVID-19, but are difficult to estimate using current …

Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies

SM Kissler, JR Fauver, C Mack, SW Olesen, C Tai… - PLoS …, 2021 - journals.plos.org
SARS-CoV-2 infections are characterized by viral proliferation and clearance phases and
can be followed by low-level persistent viral RNA shedding. The dynamics of viral RNA …

Quantifying the relationship between SARS-CoV-2 viral load and infectiousness

A Marc, M Kerioui, F Blanquart, J Bertrand, O Mitja… - Elife, 2021 - elifesciences.org
The relationship between SARS-CoV-2 viral load and infectiousness is poorly known. Using
data from a cohort of cases and high-risk contacts, we reconstructed viral load at the time of …

SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy: an observational study

GE Edelstein, J Boucau, R Uddin, C Marino… - Annals of Internal …, 2023 - acpjournals.org
Background: Data are conflicting regarding an association between treatment of acute
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …

In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness

R Ke, C Zitzmann, DD Ho… - Proceedings of the …, 2021 - National Acad Sciences
The within-host viral kinetics of SARS-CoV-2 infection and how they relate to a person's
infectiousness are not well understood. This limits our ability to quantify the impact of …

Mechanistic modeling of SARS‐CoV‐2 and other infectious diseases and the effects of therapeutics

AS Perelson, R Ke - Clinical Pharmacology & Therapeutics, 2021 - Wiley Online Library
Modern viral kinetic modeling and its application to therapeutics is a field that attracted the
attention of the medical, pharmaceutical, and modeling communities during the early days of …

Analytical sensitivity of the Abbott BinaxNOW COVID-19 Ag card

GA Perchetti, ML Huang, MG Mills… - Journal of Clinical …, 2021 - Am Soc Microbiol
Multiple rapid antigen (Ag) tests for severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have recently received emergency-use authorization (EUA) from the US Food and …